文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

慢性肾素-血管紧张素-醛固酮系统抑制剂治疗对感染性休克患者使用血管加压素的影响评价

Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论慢性RAAS抑制剂治疗的感染性休克患者使用血管加压素后6小时平均动脉压与未用药者无显著差异,但24小时 norepinephrine 等效血管加压药需求量更低。

单中心回顾性队列研究,纳入2014年1月至2015年12月接受血管加压素并至少联用一种其他血管加压药的感染性休克患者,分为慢性RAAS抑制剂组和非RAAS抑制剂组。主要终点6小时平均动脉压两组分别为72.2 mmHg和69.7 mmHg(p=0.298),无显著差异;1、24、48小时平均动脉压也无差异。24小时 norepinephrine 等效总血管加压药需求量RAAS抑制剂组显著低于非RAAS抑制剂组(10.7 vs 18.1 µg/min,p=0.007),其他时间点无显著差异。ICU或医院住院时间及死亡率无显著差异。

要点

  • 感染性休克接受血管加压素者,慢性RAAS抑制剂组6小时平均动脉压72.2 mmHg vs 非RAAS抑制剂组69.7 mmHg,p=0.298,无显著差异。
  • 24小时 norepinephrine 等效总血管加压药需求量RAAS抑制剂组10.7 µg/min vs 非RAAS抑制剂组18.1 µg/min,p=0.007,RAAS抑制剂组显著更低。
  • 1、24、48小时平均动脉压两组间均无显著差异。
  • ICU住院时间、医院住院时间及死亡率两组间均无显著差异。
  • 该研究为单中心回顾性队列,无干预措施,仅提示慢性RAAS抑制剂使用与24小时血管加压药需求量降低相关。

适用人群与场景

  • 2014年1月至2015年12月期间在1100张床位的学术医疗中心内科和外科ICU住院的感染性休克患者。
  • 接受血管加压素输注并至少联用一种其他血管加压药的患者。
  • 分为两组:门诊时正在接受慢性RAAS抑制剂治疗的患者,以及门诊时未接受慢性RAAS抑制剂治疗的患者。

研究设计与关键结果

  • 研究类型:单中心、回顾性队列研究,设置于1100张床位的学术医疗中心内科和外科ICU。
  • 人群:感染性休克接受血管加压素并至少联用一种其他血管加压药的患者,分为慢性RAAS抑制剂组和非RAAS抑制剂组。
  • 主要终点:6小时平均动脉压RAAS抑制剂组72.2 mmHg vs 非RAAS抑制剂组69.7 mmHg(p=0.298),无显著差异。
  • 次要终点:1、24、48小时平均动脉压两组间无显著差异;24小时 norepinephrine 等效总血管加压药需求量(排除血管加压素)RAAS抑制剂组10.7 µg/min vs 非RAAS抑制剂组18.1 µg/min(p=0.007),RAAS抑制剂组显著更低;其他时间点无显著差异。
  • ICU住院时间、医院住院时间及死亡率两组间无显著差异。

证据类型、等级与局限

  • 证据类型:单中心、回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于感染性休克接受血管加压素且长期服用RAAS抑制剂的患者,6小时平均动脉压目标与未服用RAAS抑制剂者无显著差异。
  • 长期服用RAAS抑制剂的患者在加用血管加压素后24小时 norepinephrine 等效血管加压药需求量可能更低(10.7 vs 18.1 µg/min),但该结果来自单中心回顾性队列,其他时间点无显著差异。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To compare the hemodynamic response in septic shock patients receiving vasopressin who were on chronic renin-angiotensin-aldosterone system inhibitor therapy with those who were not.

DESIGN: Single-center, retrospective cohort study.

SETTING: Medical and surgical ICUs at a 1,100-bed academic medical center.

PATIENTS: Medical and surgical ICU patients with septic shock who received vasopressin infusion added to at least one concomitant vasopressor agent between January 2014 and December 2015, then divided into two cohorts: 1) patients who were on chronic renin-angiotensin-aldosterone system inhibitor therapy as outpatients and 2) patients who were not on chronic renin-angiotensin-aldosterone system inhibitor therapy as outpatients.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Mean arterial pressure at 6 hours was 72.2 mm Hg in the renin-angiotensin-aldosterone system inhibitor group versus 69.7 mm Hg in the non-renin-angiotensin-aldosterone system inhibitor group (p = 0.298). There was no difference in mean arterial pressure at 1, 24, or 48 hours between groups. Total concomitant vasopressor requirements, based on norepinephrine equivalents excluding vasopressin, were significantly lower at 24 hours in the renin-angiotensin-aldosterone system inhibitor group versus the non-renin-angiotensin-aldosterone system inhibitor group (10.7 vs 18.1 µg/min, respectively; p = 0.007), but no significant differences were seen at the other time points assessed. There were no significant differences in ICU or hospital length of stay or mortality.

CONCLUSIONS: There was no significant difference in the primary outcome of 6-hour mean arterial pressure in septic shock patients receiving vasopressin who were on chronic renin-angiotensin-aldosterone system inhibitor therapy versus those receiving vasopressin who were not on chronic renin-angiotensin-aldosterone system inhibitor therapy. Renin-angiotensin-aldosterone system inhibitor patients had lower total concomitant vasopressor requirements at 24 hours compared with non-renin-angiotensin-aldosterone system inhibitor patients.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Erwin BL, Denaburg MA, Barker AB, et al. Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors. Crit Care Med. 2017. PMID: 28991825. doi:10.1097/CCM.0000000000002729

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。